Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.30 -3.22%

-$0.14 today

Market cap
$191.00M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.23M

Average 0.38M

PRLD Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Prelude Therapeutics IncorporatedNASDAQ: PRLD

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was $4.19M, compared with $0 a year earlier. Trailing-twelve-month gross profit was $16.33M.

Context

  • Gross profit amounted to 85.9% of revenue in FY2025, down 14.1 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $4.19M or moves back toward the trailing-twelve-month quarterly average of $4.08M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.19M-25.7% QoQ
Last fiscal yearDec 2025
$10.43M+49.0% YoY
LTMMar 2026
$16.33M+133.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+49.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
10.43M USD
Year-over-year change
+49.0%

Gross Profit vs competitors

How PRLD compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +133.3% is the 2nd highest of 10, against a peer median of -13.6%.
  • Gross profit amounts to 97.7% of revenue for PRLD, versus a peer median of 98.8%.
PRLD Competitors
Gross Profit for PRLD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$68M USD+5.5%-11.0%98.3%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$32.49M USD+1115.8%+118.1%99.3%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$16.33M USD+133.3%—97.7%
PYXSPyxis Oncology, Inc.LTM Mar 2026$13.83M USD——99.8%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$9.26M USD+117.7%-9.7%82.6%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$6.28M USD-73.3%+12.8%22.3%
IVAInventiva S.A.FY2025€1.51M EUR-83.6%-55.4%33.7%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$326K USD+115.4%—144.9%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026-$151.18K USD-13.6%——
IMRXImmuneering CorporationLTM Mar 2026-$793.21K USD-354.2%——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$10.62M USD-104.7%-84.1%17996.6%
Peer median (excluding PRLD) —-13.6%-10.4%98.8%

Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0007M12.14M
Cost of Revenue00001.71M
Gross Profit0007M10.43M
Gross Margin———100.0%85.9%
Research & Development86.78M92.89M103.39M118M94.3M
Selling, General & Admin26.96M30.65M28.88M28.72M22.41M
Operating Expenses113.74M123.54M132.28M146.71M115M
Depreciation & Amortization915K1.32M1.17M1.77M1.71M
EBITDA(110.78M)(114.11M)(120.66M)(125.4M)(97.79M)
EBITDA Margin———-1791.4%-805.5%
Operating Income(113.74M)(123.54M)(132.28M)(139.71M)(104.57M)
Operating Margin———-1995.9%-861.3%
Interest Income00000
Interest Expense00000
Other Income / Expenses2.04M8.1M10.44M12.54M5.07M
Income Before Tax(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Pre-Tax Margin———-1816.8%-819.6%
Income Tax Expense00000
Net Income(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Net Margin———-1816.8%-819.6%
EPS (Basic)(2.33)(2.27)(2.02)(1.68)(1.29)
EPS (Diluted)(2.33)(2.27)(2.02)(1.68)(1.29)
Weighted Avg Shares47.6M47.37M60.36M75.81M76.96M
Weighted Avg Shares (Diluted)47.6M47.37M60.36M75.81M76.96M

Prelude Therapeutics Incorporated

NASDAQ:PRLD

Intrinsic Alpha fair value

Locked

Current Price

$3.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.